IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd

₹ 90.9 -1.01%
28 Aug - close price
About

IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market.[1]

It is the largest player of Ibuprofen (pain killer) globally with a world market share of 35%.[2]

Key Points

Business Segments

  • Market Cap 2,668 Cr.
  • Current Price 90.9
  • High / Low 108 / 57.5
  • Stock P/E 25.4
  • Book Value 57.5
  • Dividend Yield 0.88 %
  • ROCE 8.87 %
  • ROE 6.13 %
  • Face Value 2.00

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 20.6%

Cons

  • Company has a low return on equity of 8.05% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
565 541 523 587 563 545 520 504 502 526 523 528 552
509 510 481 492 491 481 476 454 451 484 476 465 490
Operating Profit 56 32 43 95 73 64 44 50 51 42 47 63 62
OPM % 10% 6% 8% 16% 13% 12% 9% 10% 10% 8% 9% 12% 11%
5 5 7 9 7 7 8 8 7 6 4 5 7
Interest 3 4 5 5 4 4 4 3 2 4 4 4 4
Depreciation 11 11 12 12 14 16 16 16 17 18 19 19 20
Profit before tax 47 22 33 87 61 51 32 37 40 26 28 45 46
Tax % 26% 28% 28% 26% 25% 26% 28% 26% 24% 26% 26% 30% 25%
35 16 24 65 46 38 23 28 30 19 21 31 34
EPS in Rs 1.18 0.54 0.81 2.21 1.56 1.29 0.79 0.94 1.02 0.65 0.70 1.07 1.16
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
2,184 2,217 2,133 2,079 2,129
1,925 1,991 1,902 1,877 1,915
Operating Profit 259 226 231 202 213
OPM % 12% 10% 11% 10% 10%
17 25 30 22 22
Interest 8 16 16 15 17
Depreciation 43 46 63 72 75
Profit before tax 225 189 182 138 144
Tax % 25% 26% 26% 27%
168 139 134 101 105
EPS in Rs 5.71 4.74 4.58 3.44 3.58
Dividend Payout % 14% 17% 22% 23%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: -2%
TTM: 3%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: -17%
TTM: -11%
Stock Price CAGR
10 Years: 21%
5 Years: -12%
3 Years: 8%
1 Year: 3%
Return on Equity
10 Years: %
5 Years: %
3 Years: 8%
Last Year: 6%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 59 59 59 59
Reserves 1,334 1,449 1,553 1,629
44 80 33 117
526 435 600 577
Total Liabilities 1,962 2,022 2,244 2,382
561 752 933 1,171
CWIP 105 90 101 22
Investments 2 20 20 21
1,294 1,161 1,190 1,169
Total Assets 1,962 2,022 2,244 2,382

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024 Mar 2025
93 122 290 179
-121 -120 -191 -154
-2 -4 -92 46
Net Cash Flow -29 -2 6 70

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 79 83 81 90
Inventory Days 95 77 111 95
Days Payable 95 74 123 112
Cash Conversion Cycle 79 86 69 73
Working Capital Days 71 72 71 58
ROCE % 14% 12% 9%

Shareholding Pattern

Numbers in percentages

2 Recently
Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
43.69% 43.69% 48.19% 48.19% 48.19% 48.19% 48.19% 48.19% 48.19% 52.62% 52.62% 52.62%
2.41% 2.37% 2.43% 3.54% 2.33% 2.18% 1.40% 1.39% 1.63% 1.49% 1.47% 2.59%
0.05% 0.16% 0.23% 0.25% 0.35% 0.36% 0.29% 0.09% 0.07% 0.08% 0.07% 0.02%
53.84% 53.78% 49.15% 48.02% 49.12% 49.27% 50.11% 50.34% 50.11% 45.81% 45.84% 44.76%
No. of Shareholders 1,45,6921,43,3271,40,1771,26,0041,35,3971,34,2351,30,0031,28,6891,25,9791,26,7011,30,0021,25,040

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls